[O4] Oral Presentations 4

17:24 〜 17:31

[O4-08] A phase 1 clinical trial of a new oncolytic herpes virus expressing anti-VEGF antibody in patients with malignant glioma

*Tomoki Todo¹, Hirotaka Ito¹, Minoru Tanaka¹ (1. Institute of Medical Science, The University of Tokyo (Japan))

キーワード：

herpes simplex virus type 1、oncolytic virus therapy、malignant glioma、clinical trial、anti-VEGF antibody、bevacizumab

閲覧にはパスワードが必要です

ログイン

または